Study guide
6.3 Serology
NBCE Part III Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 TMCQ, EMCQ, and DXI Formats 1.3 Study Plan and Timed Pacing
2 Case History: Complaint and Background
2.1 Chief Complaint 2.2 Present Illness (HPI) 2.3 Past History
3 Case History: Context and Systems Review
2.4 Family History 2.5 Personal and Social History 2.6 Review of Systems
4 Physical Examination: Core Systems
3.1 General Survey 3.2 Head and Neck Examination 3.3 Thorax and Lung Examination 3.4 Cardiovascular Examination
5 Physical Examination: Specialized Regions
3.5 Breast and Axilla Examination 3.6 Abdominal Examination 3.7 Urogenital Examination 3.8 Rectal Examination
6 Neuromusculoskeletal Examination
4.1 Posture and Gait Analysis 4.2 Spinal and Extremity Orthopedic Procedures 4.3 Standard Neurological Testing 4.4 Peripheral Vascular Examination
7 Diagnostic Imaging (Clinical Domain)
5.1 Imaging Indications and Contraindications 5.2 Patient Protection and Positioning 5.3 Normal Imaging Anatomy 5.4 Description and Interpretation of Images
8 Clinical Laboratory: Core Studies
6.1 Urinalysis 6.2 Hematology 6.3 Serology 6.4 Blood Chemistries
9 Clinical Laboratory: Special Studies
6.5 Stool Analysis 6.6 Joint Fluid Analysis 6.7 Electrophysiologic Recordings (EEG, ECG, EMG, and NCV)
10 Diagnosis or Clinical Impression
7.1 Clinical Impression from History 7.2 Clinical Impression from Physical and NMS Exam 7.3 Clinical Impression from Diagnostic Imaging 7.4 Clinical Impression from Lab and Special Studies
11 Chiropractic Techniques
8.1 Indications and Contraindications for Chiropractic Care 8.2 Spinal Adjustive Techniques 8.3 Extremity Adjustive Techniques 8.4 Skeletal Biomechanics
12 Supportive Interventions: Modalities, Nutrition, Exercise
9.1 Physiotherapy Modalities 9.2 Nutrition and Diet 9.3 Corrective Exercises and Rehabilitation
13 Supportive Interventions: Ergonomics, Education, Wellness
9.4 Protective Body Mechanics and Ergonomics 9.5 Patient Education and Self-Care 9.6 Wellness and Lifestyle Counseling
14 Case Management
10.1 Treatment Plan and Prognosis 10.2 Case Follow-up and Review 10.3 Patient Referral and Co-Management 10.4 Clinical Documentation and Informed Consent
15 DXI: Arthritic Disorders
11.1 DXI Degenerative Arthritic Disorders 11.2 DXI Inflammatory Arthritic Disorders 11.3 DXI Metabolic and Crystalline Arthropathy
16 DXI: Congenital Anomalies and Skeletal Variants
12.1 DXI Spinal Congenital Anomalies 12.2 DXI Extraspinal Skeletal Variants 12.3 DXI Scoliosis Imaging
17 DXI: Trauma
13.1 DXI Skeletal Trauma 13.2 DXI Soft Tissue Trauma
18 DXI: Tumors and Tumor-like Processes
14.1 DXI Benign Bone Tumors 14.2 DXI Primary Malignant Bone Tumors 14.3 DXI Metastatic Bone Disease 14.4 DXI Tumor-like Processes
19 DXI: Miscellaneous Osteoarticular
15.1 DXI Hematological and Vascular Bone Disease 15.2 DXI Bone and Joint Infections 15.3 DXI Nutritional and Metabolic Bone Disease 15.4 DXI Endocrine Bone Disease
20 DXI: Soft Tissue
16.1 DXI Chest Soft Tissue Findings 16.2 DXI Abdomen Soft Tissue Findings 16.3 DXI Miscellaneous Soft Tissue Findings
21 Exam Strategy and Common Traps
17.1 EMCQ Case Strategy 17.2 Timed Exam Strategy and Common Traps
6.3 Serology
Key Takeaways Explain This Topic AI
Anti-CCP antibodies are more specific than rheumatoid factor for rheumatoid arthritis and can appear years before clinical symptoms develop.
ANA is a highly sensitive but poorly specific screening test; a positive result requires clinical correlation, not an automatic lupus diagnosis.
HLA-B27 is a lifelong genetic marker, not a measure of disease activity, and supports rather than confirms a diagnosis of ankylosing spondylitis, reactive arthritis, or related spondyloarthropathies.
ASO titers confirm a recent streptococcal infection and are ordered when migratory joint pain follows an untreated sore throat.
Lyme disease uses two-tier serology (EIA screening followed by Western blot confirmation), and early infection can produce a false-negative result despite a convincing clinical picture.
Last updated: July 2026
6.3 Serology
Quick Answer: Serologic testing turns a vague joint or connective-tissue complaint into a specific diagnostic direction. Rheumatoid factor and anti-CCP point toward rheumatoid arthritis, ANA screens broadly for lupus and other connective tissue disease, HLA-B27 supports the seronegative spondyloarthropathies (ankylosing spondylitis, reactive arthritis, psoriatic arthritis, IBD-associated arthritis), ASO titers confirm a recent streptococcal trigger, and two-tier Lyme serology confirms tick-borne disease. None of these tests stands alone — each only makes sense in the context of the clinical picture that prompted ordering it.
Rheumatoid Factor (RF)
RF is an antibody (usually IgM) directed against the Fc portion of IgG. It is present in roughly 70-80% of patients with established rheumatoid arthritis (RA), but its major weakness is poor specificity: RF is also positive in Sjogren's syndrome, chronic infections (hepatitis C, endocarditis), other connective tissue diseases, and in up to 5-10% of healthy older adults with no disease at all. A positive RF in isolation, without symmetric small-joint synovitis and morning stiffness lasting more than an hour, is not diagnostic of RA and should not by itself redirect a mechanical joint complaint toward a systemic diagnosis.
Anti-CCP Antibodies
Anti-cyclic citrullinated peptide (anti-CCP) antibodies are far more specific for RA than RF (specificity above 95%) and, importantly, can appear years before clinical symptoms and before RF turns positive. When a patient presents with early symmetric polyarthritis of the hands and wrists, anti-CCP is the test that most reliably confirms RA and predicts a more erosive disease course, which changes the urgency of referral to rheumatology for early disease-modifying treatment.
Antinuclear Antibody (ANA)
ANA is a screening test, not a diagnostic one. It is highly sensitive (positive in over 95% of systemic lupus erythematosus cases) but has notoriously poor specificity — a low-titer positive ANA can be found in 10-15% of the healthy general population and rises further with age, certain infections, and some medications. A positive ANA justifies further work-up (specific antibodies such as anti-dsDNA and anti-Smith, complement levels, and clinical correlation with malar rash, photosensitivity, oral ulcers, serositis, or renal involvement) rather than an automatic lupus diagnosis. A patient with diffuse joint pain and a positive ANA but none of the systemic features of lupus is far more likely to have a mechanical or fibromyalgia-type presentation than connective tissue disease.
HLA-B27
HLA-B27 is a genetic marker, not an antibody, and it does not measure disease activity — a person is either positive or negative for life. It is strongly associated with the seronegative spondyloarthropathies:
- Condition Approx. HLA-B27 Positivity
- Ankylosing spondylitis 85-95%
- Reactive arthritis 60-85%
- Psoriatic arthritis (axial) 40-50%
- IBD-associated arthritis 30-70%
- General population 6-8%
The key teaching point is that HLA-B27 is neither necessary nor sufficient for diagnosis: a patient can have ankylosing spondylitis with a negative HLA-B27, and a large fraction of HLA-B27-positive people never develop any spondyloarthropathy. The test is ordered to support a clinical suspicion already raised by history and exam — inflammatory back pain, sacroiliac tenderness, uveitis, dactylitis, or a preceding infection — not as a stand-alone screening tool for back pain in general.
Antistreptolysin O (ASO) Titer
ASO measures antibodies against streptolysin O, a toxin produced by Group A Streptococcus, and confirms a recent (within the past several weeks) streptococcal infection. It is ordered when a patient presents with migratory polyarthralgia, fever, or other features suggesting acute rheumatic fever or post-streptococcal reactive arthritis following a sore throat that may have gone untreated. A rising titer on serial testing (drawn two to four weeks apart) is more meaningful than a single value, since ASO can remain elevated for months after the acute infection has resolved.
Lyme Disease Serology
Lyme testing uses a standardized two-tier protocol:
First tier: an enzyme immunoassay (EIA/ELISA) screens for antibodies against Borrelia burgdorferi.
Second tier: if the EIA is positive or equivocal, a Western blot confirms the result by detecting antibodies against specific bacterial proteins.
Serology should be interpreted alongside exposure history and symptoms — a documented tick bite or residence/travel in an endemic region, followed by erythema migrans (the classic expanding bull's-eye rash), migratory joint pain, or facial nerve palsy. Early Lyme disease (within the first few weeks) can produce a false-negative antibody test because the immune response has not yet matured, so a clinically convincing early case should not be dismissed solely because serology is still negative.
When to Order What: A Decision Framework
- Presentation First-Line Serology
- Symmetric small-joint swelling, morning stiffness > 1 hour RF and anti-CCP
- Malar rash, photosensitivity, multisystem symptoms ANA (with reflex panel if positive)
- Young adult, inflammatory low back pain, SI joint tenderness HLA-B27
- Joint pain + preceding urethritis/conjunctivitis/dysentery HLA-B27, consider ASO if a strep history is present
- Recent sore throat, migratory joint pain ASO titer
- Tick exposure, expanding rash, migratory arthralgia Lyme two-tier serology
- Why This Matters in Practice
Serology reshapes a diagnosis by converting a purely mechanical hypothesis into a systemic or infectious one, which changes management from adjustment and rehabilitation to comanagement or referral. The recurring exam trap is treating any single positive marker as diagnostic; the correct clinical reasoning always weighs the serology against the pretest probability created by the history and physical exam findings that prompted the test in the first place.